Product Description
Mechanisms of Action: CYP26 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Barrier
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Ichthyosis, Lamellar
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Efficacy and safety of two doses of liarozole vs. placebo for the treatment of lamellar ichthyosis. | P3 |
Completed |
Ichthyosis, Lamellar |
2007-04-26 |
|
| BT0500INT001 | P3 |
Completed |
Ichthyosis, Lamellar |
2007-04-01 |